Alpha Tau Medical Ltd. DRTS

Healthcare SIC 3841 - Surgical & Medical Instruments & Apparatus NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical and Medical Instrument Manufacturing derived Nasdaq

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.53

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
R&D $32.1M$27.0M$26.4M$20.9M$11.4M$7.5M$6.6M—
SG&A $8.4M$6.7M$7.3M$10.3M$1.9M$1.4M$977.0K—
Operating income -$42.3M-$36.0M-$35.7M-$32.1M-$13.8M-$9.2M$8.0M—
Interest expense $347.0K$303.0K$75.0K—————
Pre-tax income -$42.5M-$31.7M-$29.1M-$33.7M-$27.3M-$8.7M$8.3M—
Income tax $121.0K$6.0K$16.0K$20.0K$7.0K$158.0K$146.0K—
Net income -$42.6M-$31.8M-$29.2M-$33.8M-$27.3M-$8.9M-$8.4M—
EPS, basic -0.53-0.45-0.42-0.53-0.67-0.22-0.25—
EPS, diluted -0.53-0.45-0.42-0.53-0.67-0.22-0.25—
Shares, diluted (wtd. avg.) 80.6M69.9M69.4M63.5M40.5M40.3M33.8M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents $12.2M$13.7M$12.7M$6.7M$23.9M$16.2M$1.8M$13.6M
Short-term investments $60.9M$45.9M$69.1M$98.7M$8.1M———
Total current assets $78.3M$64.2M$85.8M$106.5M$32.6M$47.5M——
Property, plant and equipment $19.7M$13.9M$12.8M$7.5M$7.5M$5.4M——
Total assets $105.7M$86.2M$107.4M$120.1M$42.2M$53.0M——
Accounts payable ——$2.6M$1.4M$1.2M$964.0K——
Total current liabilities $10.5M$8.7M$7.1M$4.3M$4.4M$2.1M——
Long-term debt ——$5.2M—————
Total liabilities $28.6M$23.5M$22.9M$14.5M$23.0M$7.5M——
Retained earnings -$190.1M-$147.5M-$115.8M-$86.6M-$52.8M-$25.6M——
Total equity $77.1M$62.7M$84.5M$105.7M-$34.8M-$8.4M-$193.0K$1.9M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Operating cash flow -$26.7M-$19.8M-$18.0M-$23.9M-$11.8M-$7.3M-$6.9M—
Depreciation and amortisation $1.2M$1.1M$1.1M$979.0K$776.0K$86.0K$66.0K—
Stock-based compensation $10.6M$9.9M$7.9M$6.7M$812.0K$596.0K$546.0K—
Capital expenditure $6.1M$2.2M$6.4M$904.0K$2.9M$3.8M$1.3M—
Investing cash flow -$20.6M$20.8M$18.7M-$89.9M$19.3M-$7.8M-$10.2M—
Financing cash flow $45.8M$25.0K$5.3M$96.9M$111.0K$29.3M$5.3M—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-025174.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Total current liabilities
  • Depreciation and amortisation
  • Operating cash flow
  • Total current assets
Total current liabilities, Depreciation and amortisation, Operating cash flow, Total current assets by fiscal year, in US dollars The same figures are in the table below this chart. -50M 0 50M 100M 150M Depreciation and amortisation, FY2019: 66K Operating cash flow, FY2019: -6.9M Total current liabilities, FY2020: 2.1M Depreciation and amortisation, FY2020: 86K Operating cash flow, FY2020: -7.3M Total current assets, FY2020: 47.5M Total current liabilities, FY2021: 4.4M Depreciation and amortisation, FY2021: 776K Operating cash flow, FY2021: -11.8M Total current assets, FY2021: 32.6M Total current liabilities, FY2022: 4.3M Depreciation and amortisation, FY2022: 979K Operating cash flow, FY2022: -23.9M Total current assets, FY2022: 106.5M Total current liabilities, FY2023: 7.1M Depreciation and amortisation, FY2023: 1.1M Operating cash flow, FY2023: -18M Total current assets, FY2023: 85.8M Total current liabilities, FY2024: 8.7M Depreciation and amortisation, FY2024: 1.1M Operating cash flow, FY2024: -19.8M Total current assets, FY2024: 64.2M Total current liabilities, FY2025: 10.5M Depreciation and amortisation, FY2025: 1.2M Operating cash flow, FY2025: -26.7M Total current assets, FY2025: 78.3M FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Total current liabilities — — $2.1M $4.4M $4.3M $7.1M $8.7M $10.5M
Depreciation and amortisation — $66.0K $86.0K $776.0K $979.0K $1.1M $1.1M $1.2M
Operating cash flow — -$6.9M -$7.3M -$11.8M -$23.9M -$18.0M -$19.8M -$26.7M
Total current assets — — $47.5M $32.6M $106.5M $85.8M $64.2M $78.3M

Others in SIC 3841

TickerCompanyMarket capP/ERevenue growth
SYK STRYKER CORP $116.27B 36.1x 11.2%
MMM 3M CO $86.93B 28.1x 1.5%
BSX BOSTON SCIENTIFIC CORP $69.27B 24.6x 19.9%
BDX BECTON DICKINSON & CO $50.32B 31.7x 8.2%
DXCM DEXCOM INC $33.17B 42.1x 15.6%
RMD RESMED INC $32.94B 21.9x 9.9%
MDLN Medline Inc. $31.35B — 11.5%
WST WEST PHARMACEUTICAL SERVICES INC $23.93B 50.1x 6.3%